Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,483
archived clinical trials in
Influenza

Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Metairie, LA
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Metairie, LA
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Norfolk, NE
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Norfolk, NE
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Omaha, NE
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Syracuse, NY
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Syracuse, NY
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Dayton, OH
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Dayton, OH
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Grove City, OH
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Grove City, OH
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Gresham, OR
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Gresham, OR
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Erie, PA
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Erie, PA
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Charleston, SC
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Tullahoma, TN
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Tullahoma, TN
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Fort Worth, TX
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Houston, TX
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Layton, UT
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Layton, UT
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Orem, UT
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Orem, UT
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Provo, UT
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Provo, UT
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Roy, UT
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Roy, UT
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
South Jordan, UT
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
South Jordan, UT
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
West Jordan, UT
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
West Jordan, UT
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Burke, VA
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Burke, VA
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Sacramento, CA
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Thornton, CO
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Thornton, CO
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Miami Beach, FL
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Bardstown, KY
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Bardstown, KY
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Lincoln, NE
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated:  3/6/2018
Clinical Research Facility
mi
from
Anaheim, CA
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children
Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age
Status: Enrolling
Updated: 3/6/2018
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
Evaluation of the School Kids Influenza Prevention Project
Evaluation of a Text Based Reminder Recall System to Increase Utilization of the School Kids Influenza Prevention Project and Increase Influenza Vaccination Rates in Monroe County, NY
Status: Enrolling
Updated:  3/9/2018
Univ of Rochester Medical Center
mi
from
Rochester, NY
Evaluation of the School Kids Influenza Prevention Project
Evaluation of a Text Based Reminder Recall System to Increase Utilization of the School Kids Influenza Prevention Project and Increase Influenza Vaccination Rates in Monroe County, NY
Status: Enrolling
Updated: 3/9/2018
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.
Phase IV, Pilot, Randomized, Investigator-blinded, Study to Evaluate the Reactogenicity and Immunogenicity of Standard-dose Versus High-dose Inactivated Influenza Vaccine After Kidney, Heart and Lung Transplantation.
Status: Enrolling
Updated:  3/12/2018
Inova Fairfax Hospital
mi
from
Falls Church, VA
Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.
Phase IV, Pilot, Randomized, Investigator-blinded, Study to Evaluate the Reactogenicity and Immunogenicity of Standard-dose Versus High-dose Inactivated Influenza Vaccine After Kidney, Heart and Lung Transplantation.
Status: Enrolling
Updated: 3/12/2018
Inova Fairfax Hospital
mi
from
Falls Church, VA
Click here to add this to my saved trials
Immune Response Following Seasonal Influenza Vaccination
Extent and Durability of Immune Response Following Seasonal Influenza Vaccination in Healthy Volunteers
Status: Enrolling
Updated:  3/16/2018
Optimal Health Research
mi
from
Rockville, MD
Immune Response Following Seasonal Influenza Vaccination
Extent and Durability of Immune Response Following Seasonal Influenza Vaccination in Healthy Volunteers
Status: Enrolling
Updated: 3/16/2018
Optimal Health Research
mi
from
Rockville, MD
Click here to add this to my saved trials
QuickVue Influenza A + B Test Field Study
QuickVue Influenza A + B Test Field Study
Status: Enrolling
Updated:  3/16/2018
Alliance Urgent Care
mi
from
Phoenix, AZ
QuickVue Influenza A + B Test Field Study
QuickVue Influenza A + B Test Field Study
Status: Enrolling
Updated: 3/16/2018
Alliance Urgent Care
mi
from
Phoenix, AZ
Click here to add this to my saved trials
QuickVue Influenza A + B Test Field Study
QuickVue Influenza A + B Test Field Study
Status: Enrolling
Updated:  3/16/2018
Twelve Corners Pediatrics
mi
from
Rochester, NY
QuickVue Influenza A + B Test Field Study
QuickVue Influenza A + B Test Field Study
Status: Enrolling
Updated: 3/16/2018
Twelve Corners Pediatrics
mi
from
Rochester, NY
Click here to add this to my saved trials
QuickVue Influenza A + B Test Field Study
QuickVue Influenza A + B Test Field Study
Status: Enrolling
Updated:  3/16/2018
Veritas, PA
mi
from
Belton, TX
QuickVue Influenza A + B Test Field Study
QuickVue Influenza A + B Test Field Study
Status: Enrolling
Updated: 3/16/2018
Veritas, PA
mi
from
Belton, TX
Click here to add this to my saved trials
QuickVue Influenza A + B Test Field Study
QuickVue Influenza A + B Test Field Study
Status: Enrolling
Updated:  3/16/2018
City Doc Urgent Care
mi
from
Dallas, TX
QuickVue Influenza A + B Test Field Study
QuickVue Influenza A + B Test Field Study
Status: Enrolling
Updated: 3/16/2018
City Doc Urgent Care
mi
from
Dallas, TX
Click here to add this to my saved trials
QuickVue Influenza A + B Test Field Study
QuickVue Influenza A + B Test Field Study
Status: Enrolling
Updated:  3/16/2018
Advanced Pediatrics
mi
from
Vienna, VA
QuickVue Influenza A + B Test Field Study
QuickVue Influenza A + B Test Field Study
Status: Enrolling
Updated: 3/16/2018
Advanced Pediatrics
mi
from
Vienna, VA
Click here to add this to my saved trials
Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy
Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy
Status: Enrolling
Updated:  3/17/2018
Midwestern University/Northwestern Memorial Hospital
mi
from
Chicago, IL
Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy
Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy
Status: Enrolling
Updated: 3/17/2018
Midwestern University/Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Mesa, AZ
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Mesa, AZ
Click here to add this to my saved trials
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Phoenix, AZ
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Clearwater, FL
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
DeLand, FL
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
DeLand, FL
Click here to add this to my saved trials
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Delray Beach, FL
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Delray Beach, FL
Click here to add this to my saved trials
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Jacksonville, FL
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Chicago, IL
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Wichita, KA
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Wichita, KA
Click here to add this to my saved trials
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Lexington, KY
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Lexington, KY
Click here to add this to my saved trials
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Columbia, MD
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Columbia, MD
Click here to add this to my saved trials
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Rockville, MD
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Rockville, MD
Click here to add this to my saved trials
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Milford, MA
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Milford, MA
Click here to add this to my saved trials
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Kansas City, MO
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Kansas City, MO
Click here to add this to my saved trials
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Somers Point, NJ
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Somers Point, NJ
Click here to add this to my saved trials
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Binghamton, NY
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Binghamton, NY
Click here to add this to my saved trials
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated:  3/19/2018
GSK Investigational Site
mi
from
Camillus, NY
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
A Study to Evaluate the Safety, Immunogenicity, and Relative Efficacy of A/California/7/2009 (H1N1)V-like Vaccines GSK2340274A and GSK2340273A in Adults Aged 18 Years and Older
Status: Enrolling
Updated: 3/19/2018
GSK Investigational Site
mi
from
Camillus, NY
Click here to add this to my saved trials